{"id":"combination-lysine-acetylsalicylate-clopidogrel","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal hemorrhage"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Bruising"}]},"_chembl":{"chemblId":"CHEMBL1697753","moleculeType":"Small molecule","molecularWeight":"326.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lysine acetylsalicylate (aspirin) acetylates cyclooxygenase-1, preventing thromboxane A2 production and platelet aggregation. Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-induced platelet activation. Together, they provide dual antiplatelet effects through distinct mechanisms, reducing thrombotic events more effectively than monotherapy.","oneSentence":"This combination inhibits platelet aggregation through two complementary pathways: lysine acetylsalicylate irreversibly blocks thromboxane A2 synthesis, while clopidogrel inhibits ADP-mediated platelet activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:09.078Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Secondary prevention of cardiovascular events post-acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT02817789","phase":"PHASE3","title":"Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-05-09","conditions":"Aortic Valve Stenosis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Combination lysine acetylsalicylate - clopidogrel","genericName":"Combination lysine acetylsalicylate - clopidogrel","companyName":"University Hospital, Bordeaux","companyId":"university-hospital-bordeaux","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits platelet aggregation through two complementary pathways: lysine acetylsalicylate irreversibly blocks thromboxane A2 synthesis, while clopidogrel inhibits ADP-mediated platelet activation. Used for Acute coronary syndrome, Secondary prevention of cardiovascular events post-acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}